BioSpace News Archive

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced operational results for the first quarter ended March 31, 2022.

Sitryx Therapeutics Ltd, a biopharmaceutical company pioneering the field of immunometabolism, announced the appointment of Dr. Ravi M. Rao as its Chief Medical Officer.

ReiThera Srl and Exothera announced that they have entered into a collaboration agreement to develop a large-scale, low cost per dose manufacturing process for the production of ReiThera’s novel vaccines.

Engitix Ltd, a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix platform, entered into an agreement with Takeda to expand an existing collaboration to now include the discovery and development of novel therapeutics for fibrostenotic inflammatory bowel disease, including Crohn’s disease and ulcerative colitis.

The Annual General Meeting of Promore Pharma AB will be held on Tuesday, 17 May 2022 at 2 pm, in the premises of Wennergren Center, Biblioteket, floor 24, Sveavägen 166, in Stockholm.

Keymed Biosciences announced that its new drug candidate CMG901 for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma has been granted the Orphan-drug Designation by the Food and Drug Administration of the United States recently.

Deerfield Partner Andrew ElBardissi, M.D. and Petrichor Partner Patrick Lally to Join Aurion Biotech Board Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, announced it has secured a $120 million financing with top-tier biotech and ophthalmology investors.

Devyser announces a strengthening of its commercial organization with the appointment of Theis Kipling as Chief Commercial Officer with global responsibility for sales, marketing, product management and tech support.

Allelica, a leading genomics software company that develops digital tools to develop, validate and calculate polygenic risk scores for common diseases, is teaming with Thomas Fernandez, MD of Yale School of Medicine in a research project aimed at uncovering the genetic basis for multiple childhood neuropsychiatric disorders.

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, announced that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for pegzilarginase for the treatment of Arginase 1 Deficiency.